 |
0 Products |  |
0 Diseases | | 0 Products |
|
0 Trials |  |
1 News |  |
| «12...234567891011121314 |
- ||||| Aidixi (disitamab vedotin) / Pfizer
New P1/2 trial, Metastases: C003 CANCER: A Study of RC48-ADC in Subjects With Advanced Breast Cancer (clinicaltrials.gov) - Feb 14, 2017
P1/2, N=165, Recruiting, Sponsor: RemeGen
- || Tai'ai (telitacicept) / Rongchang Pharma
New P3 trial: A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects with Inadequate Response to MTX Due to Treat Moderate and Severe Rheumatoid Arthritis. (clinicaltrials.gov) - Jan 10, 2017
P3, N=480, Recruiting, Sponsor: RemeGen
- Aidixi (disitamab vedotin) / Pfizer
Trial primary completion date, Metastases: C001 CANCER: A Study of RC48-ADC in Subjects With HER2-Positive Advanced Malignant Solid Tumors (clinicaltrials.gov) - Jan 6, 2017
P1, N=50, Recruiting, Sponsor: RemeGen
Trial primary completion date: Dec 2016 --> Jun 2017
- | Tai'ai (telitacicept) / Rongchang Pharma
New P2b trial: Study of RC18 Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE) (clinicaltrials.gov) - Aug 30, 2016
P2b, N=160, Recruiting, Sponsor: RemeGen
- | Tai'ai (telitacicept) / Rongchang Pharma
New P2 trial: A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Inadequate Response to TNF-? Antagonists Due to Treat Moderate and Severe Rheumatoid Arthritis (clinicaltrials.gov) - Aug 28, 2016
P2, N=60, Recruiting, Sponsor: RemeGen
- Aidixi (disitamab vedotin) / Pfizer
New P1 trial, Metastases: C001 CANCER: A Study of RC48-ADC in Subjects With HER2-Positive Advanced Malignant Solid Tumors (clinicaltrials.gov) - Aug 25, 2016
P1, N=50, Recruiting, Sponsor: RemeGen
- Aidixi (disitamab vedotin) / Rongchang Pharma, Pfizer
New P1 trial, Metastases: Study of RC48-ADC Administered Intravenously to Subjects With HER2-Positive in Advanced Malignant Solid Tumors (clinicaltrials.gov) - Aug 25, 2016
P1, N=50, Recruiting, Sponsor: RemeGen